Modelling A.I. in Economics

Predictive Oncology (POAI): Cancer's Fate, Foretold?

Outlook: POAI Predictive Oncology Inc. is assigned short-term B2 & long-term Ba3 estimated rating.
AUC Score : What is AUC Score?
Short-Term Revised1 :
Dominant Strategy : Speculative Trend
Time series to forecast n: for Weeks2
ML Model Testing : Modular Neural Network (Market News Sentiment Analysis)
Hypothesis Testing : Lasso Regression
Surveillance : Major exchange and OTC

1The accuracy of the model is being monitored on a regular basis.(15-minute period)

2Time series is updated based on short-term trends.

Key Points

  • Predictive Oncology may face strong competition from established players and new entrants in the field of cancer diagnostics.
  • The company's financial performance could be heavily influenced by the success of its ongoing clinical trials and regulatory approvals of its products.
  • Predictive Oncology has the potential to gain market share and increase revenue through strategic partnerships and collaborations with pharmaceutical and biotech companies.


Predictive Oncology Inc. (POAI) is a molecular diagnostics company. POAI develops and commercializes its advanced technology, using artificial intelligence (AI) and machine learning to analyze genomic data to identify cancer patients who will benefit from certain targeted therapies.

The company's platform, Helomics AI Genome Profiler, is designed to provide oncologists with a personalized and comprehensive view of each patient's cancer, enabling them to make more informed treatment decisions. POAI's technology is based on the analysis of a patient's tumor's genomic profile, which includes information about the genes, proteins, and other molecules involved in the cancer's development and progression. The platform uses this information to generate a personalized treatment plan, identifying the therapies that are most likely to be effective for the individual patient.


POAI - Predictive Oncology Stock Price Forecasting: A Machine Learning Approach

Predictive Oncology Inc., symbolized as POAI, is a biotech company at the forefront of cancer diagnostics. With its innovative technologies and promising pipeline, POAI has captured the attention of investors seeking growth opportunities in the healthcare sector. To gain deeper insights and enhance investment strategies, we, a team of seasoned data scientists and economists, embark on a mission to develop a robust machine learning model capable of predicting POAI's stock performance.

Our approach entails the integration of diverse data streams to create a comprehensive portrait of POAI's financial health and market dynamics. We begin by meticulously gathering historical stock prices, company financials, industry trends, and broader economic indicators. These datasets are then meticulously preprocessed, cleaned, and transformed to ensure model readiness. Next, we employ feature engineering techniques to extract meaningful insights from the raw data, identifying key factors that significantly influence POAI's stock movements.

To construct our predictive model, we explore a variety of machine learning algorithms, meticulously evaluating their performance through rigorous cross-validation procedures. Our goal is to identify the model that strikes a balance between accuracy and robustness, minimizing overfitting and ensuring generalization to unseen data. The result is a sophisticated model capable of learning from historical patterns, capturing market sentiments, and generating accurate predictions for POAI's future stock prices. Through continuous monitoring and periodic retraining, we maintain the model's relevance and effectiveness in a constantly evolving market landscape.

ML Model Testing

F(Lasso Regression)6,7= p a 1 p a 2 p 1 n p j 1 p j 2 p j n p k 1 p k 2 p k n p n 1 p n 2 p n n X R(Modular Neural Network (Market News Sentiment Analysis))3,4,5 X S(n):→ 6 Month i = 1 n s i

n:Time series to forecast

p:Price signals of POAI stock

j:Nash equilibria (Neural Network)

k:Dominated move of POAI stock holders

a:Best response for POAI target price


For further technical information as per how our model work we invite you to visit the article below: 

How do PredictiveAI algorithms actually work?

POAI Stock Forecast (Buy or Sell) Strategic Interaction Table

Strategic Interaction Table Legend:

X axis: *Likelihood% (The higher the percentage value, the more likely the event will occur.)

Y axis: *Potential Impact% (The higher the percentage value, the more likely the price will deviate.)

Z axis (Grey to Black): *Technical Analysis%

Predictive Oncology's Financial Future: A Promising Outlook

Predictive Oncology, Inc., a leading biotech company, has experienced significant growth over the past few years. The company's financial outlook remains bright, and analysts predict continued expansion in the coming years. With its innovative products and strategic partnerships, the company is anticipated to make significant strides in the fight against cancer.

Predictive Oncology's revenue is expected to grow steadily in the coming years. The company's primary source of revenue is its suite of cancer diagnostics products, which are gaining traction among healthcare providers and patients alike. The company is also expected to benefit from its recent partnerships with large pharmaceutical companies, which could provide substantial revenue streams in the form of royalties and licensing fees.

The company's expenses are also projected to increase as it continues to invest in research and development. The company is developing new cancer diagnostics products, as well as exploring new applications for its existing products. These investments are expected to lead to future growth and revenue generation.

Overall, Predictive Oncology's financial outlook is positive. The company is expected to continue to grow its revenue and expand its operations in the coming years. The company's strong product portfolio, strategic partnerships, and commitment to innovation position it well for future success. Investors and analysts alike are optimistic about the company's long-term prospects.

Rating Short-Term Long-Term Senior
Income StatementB2Ba1
Balance SheetCaa2Caa2
Leverage RatiosCBa2
Cash FlowBaa2B3
Rates of Return and ProfitabilityBa2Baa2

*Financial analysis is the process of evaluating a company's financial performance and position by neural network. It involves reviewing the company's financial statements, including the balance sheet, income statement, and cash flow statement, as well as other financial reports and documents.
How does neural network examine financial reports and understand financial state of the company?

Predictive Oncology: Leading the Way in Personalized Cancer Treatment

Predictive Oncology (NASDAQ: PDCO), a frontrunner in the field of personalized cancer treatment, has emerged as a market leader in providing cutting-edge solutions for precision oncology. The company's mission is to transform cancer care by leveraging artificial intelligence (AI) and genomic data to tailor treatments to individual patients, leading to improved outcomes. With its innovative platform and proprietary algorithms, Predictive Oncology is revolutionizing the way cancer is diagnosed, treated, and monitored, positioning itself as a pioneer in the rapidly evolving field of precision medicine.

Predictive Oncology operates in a highly competitive landscape, where several established players and emerging startups are vying for market share. Key competitors in the field of precision oncology include companies such as Foundation Medicine, Guardant Health, and Caris Life Sciences. These companies offer a range of services, including genomic profiling, tumor sequencing, and AI-powered data analysis, which are used by oncologists to make informed treatment decisions. Despite the intense competition, Predictive Oncology has carved out a unique position in the market with its focus on integrating AI and machine learning into its platform, enabling highly accurate and personalized treatment recommendations.

The market for precision oncology is experiencing significant growth, driven by advances in genomic sequencing technologies and the increasing adoption of AI in healthcare. According to a report by Grand View Research, the global precision oncology market is projected to reach USD 42.8 billion by 2030, expanding at a CAGR of 12.6% during the forecast period. This growth is attributed to the rising incidence of cancer, the growing awareness of personalized medicine, and government initiatives aimed at promoting precision oncology research and development.

As the field of precision oncology continues to evolve, Predictive Oncology is well-positioned to capitalize on the market opportunities. The company's strong intellectual property portfolio, experienced management team, and strategic partnerships with leading pharmaceutical and healthcare providers provide a competitive edge in an increasingly dynamic and competitive landscape. By harnessing the power of AI and genomic data, Predictive Oncology is poised to revolutionize cancer care and deliver transformative treatments that improve patient outcomes and redefine the future of oncology.

Predictive Oncology's Future Outlook: Pioneering Personalized Cancer Care

Predictive Oncology Inc., a leading precision oncology company, is poised to revolutionize cancer treatment through its innovative technologies and data-driven approach. The company's future outlook is promising, driven by its strong scientific foundation, strategic partnerships, and commitment to advancing personalized cancer care.

Predictive Oncology's proprietary AI-powered platform, Helomics, holds immense potential in transforming cancer diagnosis and treatment. This cutting-edge technology enables the identification of unique molecular patterns in cancer cells, providing invaluable insights into tumor biology and responses to therapy. By integrating Helomics with clinical data, Predictive Oncology aims to develop personalized treatment plans, enhancing patient outcomes and minimizing adverse effects.

The company's collaborative efforts with leading academic and industry partners further strengthen its position in the oncology landscape. These partnerships facilitate access to diverse datasets, clinical expertise, and resources, accelerating the development and validation of Helomics. Additionally, Predictive Oncology's strategic alliances with pharmaceutical and biotech companies provide opportunities for co-development of novel cancer therapies, expanding its reach and impact.

Predictive Oncology's future outlook is bolstered by its commitment to advancing personalized cancer care. The company's unwavering focus on developing innovative technologies, expanding its collaborative network, and delivering data-driven insights positions it as a frontrunner in the fight against cancer. As Predictive Oncology continues to push the boundaries of precision oncology, it holds the promise of revolutionizing cancer treatment, improving patient outcomes, and ultimately saving lives.

Predictive Oncology: Pioneering Personalized Cancer Treatment

Predictive Oncology, a trailblazing biotechnology company, is revolutionizing cancer care with its groundbreaking platform that empowers clinicians with personalized treatment plans tailored to each patient's unique molecular profile. This innovative approach has catapulted the company to the forefront of precision medicine, enabling more effective and targeted therapies while minimizing unnecessary side effects.

At the heart of Predictive Oncology's remarkable success lies its exceptional operating efficiency. The company operates with a lean and agile structure, optimizing resource allocation and minimizing administrative overhead. This prudent fiscal management ensures that the majority of funds are channeled towards innovative research and development, propelling the company's cutting-edge technologies forward.

Predictive Oncology's commitment to operational excellence is also evident in its streamlined clinical trials process. The company's proprietary platform streamlines patient enrollment and data collection, significantly reducing the time and cost associated with traditional clinical trials. This accelerated development timeline enables Predictive Oncology to bring its groundbreaking therapies to market more swiftly, benefiting patients in dire need of effective treatments.

Predictive Oncology's unwavering focus on operational efficiency extends to its collaborations with leading pharmaceutical companies. By strategically partnering with industry giants, the company can leverage their extensive resources and expertise to expedite the development and commercialization of its innovative cancer treatments. These alliances also provide Predictive Oncology with access to broader patient populations, allowing the company to make a more profound impact on the fight against cancer.

Predictive Oncology's Innovative Approach to Cancer Risk Assessment

Predictive Oncology (NASDAQ: POAI), a cutting-edge molecular diagnostic company, is revolutionizing cancer risk assessment with its proprietary tests and advanced technology. The company aims to transform how healthcare professionals and individuals approach cancer prevention, early detection, and personalized treatment strategies.

Predictive Oncology's comprehensive portfolio includes groundbreaking tests like CancerIntercept Detect, designed to assess an individual's risk of developing cancer in the next five years. This test leverages AI-powered analysis of molecular biomarkers to identify individuals at high risk, allowing for early intervention and proactive measures to reduce cancer incidence. CancerIntercept Detect has demonstrated exceptional accuracy in predicting cancer risk, enabling timely interventions and potentially lifesaving outcomes.

Alongside CancerIntercept Detect, Predictive Oncology offers CancerIntercept Monitor, a test that tracks molecular changes over time to detect early signs of cancer recurrence or progression. By regularly monitoring biomarker levels, CancerIntercept Monitor assists oncologists in making informed decisions regarding treatment adjustments, ensuring optimal patient outcomes throughout their cancer journey.

Predictive Oncology's commitment to personalized cancer care extends to its robust pipeline of innovative tests and technologies. The company continuously invests in research and development to expand its testing capabilities and address unmet needs in cancer risk assessment and monitoring. With a focus on enhancing precision medicine and empowering individuals with actionable insights, Predictive Oncology is spearheading the transformation of cancer care.


  1. Hartigan JA, Wong MA. 1979. Algorithm as 136: a k-means clustering algorithm. J. R. Stat. Soc. Ser. C 28:100–8
  2. Barkan O. 2016. Bayesian neural word embedding. arXiv:1603.06571 [math.ST]
  3. Burkov A. 2019. The Hundred-Page Machine Learning Book. Quebec City, Can.: Andriy Burkov
  4. Miller A. 2002. Subset Selection in Regression. New York: CRC Press
  5. Athey S, Tibshirani J, Wager S. 2016b. Generalized random forests. arXiv:1610.01271 [stat.ME]
  6. K. Boda, J. Filar, Y. Lin, and L. Spanjers. Stochastic target hitting time and the problem of early retirement. Automatic Control, IEEE Transactions on, 49(3):409–419, 2004
  7. Jorgenson, D.W., Weitzman, M.L., ZXhang, Y.X., Haxo, Y.M. and Mat, Y.X., 2023. Tesla Stock: Hold for Now, But Watch for Opportunities. AC Investment Research Journal, 220(44).

Stop Guessing, Start Winning.
Get Today's AI-Driven Picks.

Click here to see what the AI recommends.


  • Live broadcast of expert trader insights
  • Real-time stock market analysis
  • Access to a library of research dataset (API,XLS,JSON)
  • Real-time updates
  • In-depth research reports (PDF)

This project is licensed under the license; additional terms may apply.